Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

New Advanced Strategies For The Treatment Of Lysosomal Diseases Affecting The Central Nervous System.

M. R. Gigliobianco, P. Di Martino, S. Deng, Cristina Casadidio, R. Censi
Published 2019 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Lysosomal Storage Disorders (LSDs), also known as lysosomal diseases (LDs) are a group of serious genetic diseases characterized by not only the accumulation of non-catabolized compounds in the lysosomes due to the deficiency of specific enzymes which usually eliminate these compounds, but also by trafficking, calcium changes and acidification. LDs mainly affect the central nervous system (CNS), which is difficult to reach for drugs and biological molecules due to the presence of the blood-brain barrier (BBB). While some therapies have proven highly effective in treating peripheral disorders in LD patients, they fail to overcome the BBB. Researchers have developed many strategies to circumvent this problem, for example, by creating carriers for enzyme delivery, which improve the enzyme's half-life and the overexpression of receptors and transporters in the luminal or abluminal membranes of the BBB. This review aims to successfully examine the strategies developed during the last decade for the treatment of LDs, which mainly affect the CNS. Among the LD treatments, enzyme-replacement therapy (ERT) and gene therapy have proven effective, while nanoparticle, fusion protein, and small molecule-based therapies seem to offer considerable promise to treat the CNS pathology. This work also analyzed the challenges of the study to design new drug delivery systems for the effective treatment of LDs. Polymeric nanoparticles and liposomes are explored from their technological point of view and for the most relevant preclinical studies showing that they are excellent choices to protect active molecules and transport them through the BBB to target specific brain substrates for the treatment of LDs.
This paper references
10.1016/j.expneurol.2016.07.011
Accumulated α-synuclein affects the progression of GM2 gangliosidoses
K. Suzuki (2016)
10.1002/adhm.201500746
α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration.
I. Cabrera (2016)
10.1016/j.brainres.2006.03.116
Ex vivo cell-mediated gene therapy for metachromatic leukodystrophy using neurospheres
K. Kawabata (2006)
10.1186/1471-2164-12-S3-S22
A comparative structural bioinformatics analysis of inherited mutations in β-D-Mannosidase across multiple species reveals a genotype-phenotype correlation
T. Huynh (2011)
10.1146/annurev-med-122313-085916
Lysosomal storage diseases: from pathophysiology to therapy.
G. Parenti (2015)
10.1016/j.beem.2008.11.001
Best practice & research clinical endocrinology & metabolism. Thyroid nodules and cancer. Preface.
F. Pacini (2008)
10.1074/jbc.M111.293795
Crystal Structure of Human β-Galactosidase
U. Ohto (2011)
10.1186/1477-3155-10-20
Encapsulation of Alpha-1 antitrypsin in PLGA nanoparticles: In Vitro characterization as an effective aerosol formulation in pulmonary diseases
N. Pirooznia (2012)
Types A and B Niemann-Pick Disease.
E. Schuchman (2016)
10.1111/ped.12636
Sanfilippo syndrome: Overall review
F. Andrade (2015)
Update on treatment of lysosomal storage diseases.
S. Bruni (2007)
10.1124/dmd.111.042903
Brain-Penetrating IgG-Iduronate 2-Sulfatase Fusion Protein for the Mouse
Qing-hui Zhou (2012)
10.1007/s11095-014-1508-y
Laronidase-Functionalized Multiple-Wall Lipid-Core Nanocapsules: Promising Formulation for a More Effective Treatment of Mucopolysaccharidosis Type I
F. Q. Mayer (2014)
10.1124/jpet.107.133298
Delivery of Acid Sphingomyelinase in Normal and Niemann-Pick Disease Mice Using Intercellular Adhesion Molecule-1-Targeted Polymer Nanocarriers
C. Garnacho (2008)
10.1515/hsz-2014-0301
Innate immune responses in the brain of sphingolipid lysosomal storage diseases
Einat B. Vitner (2015)
10.1111/j.1471-4159.2012.07835.x
Mechanism of Mn(II)‐mediated dysregulation of glutamine–glutamate cycle: focus on glutamate turnover
M. Sidoryk-Węgrzynowicz (2012)
10.1016/J.BBAPAP.2006.08.012
Small molecule pharmacological chaperones: From thermodynamic stabilization to pharmaceutical drugs.
T. Arakawa (2006)
10.1002/mds.23774
Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond
Tamar Shachar (2011)
10.1056/NEJM199105233242104
Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.
N. Barton (1991)
10.1016/j.gene.2017.11.052
Mucolipidosis type III gamma: Three novel mutation and genotype-phenotype study in eleven patients.
B. Tüysüz (2018)
10.1016/j.jconrel.2018.07.043
Dual functionalized liposome‐mediated gene delivery across triple co‐culture blood brain barrier model and specific in vivo neuronal transfection
Bruna dos Santos Rodrigues (2018)
10.1016/J.YMTHE.2006.01.006
Gene therapy for lysosomal storage diseases.
M. Sands (2006)
10.1007/s00234-009-0548-1
Apparent diffusion coefficient vale of the brain in patients with Gaucher’s disease type II and type III
A. A. A. Abdel Razek (2009)
10.1186/s13023-014-0132-6
Towards the targeted management of Chediak-Higashi syndrome
M. Lozano (2014)
10.1016/j.bbamcr.2008.11.015
Molecular basis of multiple sulfatase deficiency, mucolipidosis II/III and Niemann-Pick C1 disease - Lysosomal storage disorders caused by defects of non-lysosomal proteins.
T. Dierks (2009)
10.1126/science.1174447
A Gene Network Regulating Lysosomal Biogenesis and Function
M. Sardiello (2009)
10.1523/JNEUROSCI.3584-04.2004
Intracerebral Transplantation of Adult Mouse Neural Progenitor Cells into the Niemann-Pick-A Mouse Leads to a Marked Decrease in Lysosomal Storage Pathology
L. Shihabuddin (2004)
Depletion of rafts in late endocytic membranes is controlled by NPC1-dependent recycling of cholesterol to the plasma membrane.
S. Lusa (2001)
10.1016/j.stem.2009.05.022
Neuroprotection of host cells by human central nervous system stem cells in a mouse model of infantile neuronal ceroid lipofuscinosis.
S. Tamaki (2009)
10.1016/j.pneurobio.2016.10.002
Emerging therapies for neuropathic lysosomal storage disorders
J. Kelly (2017)
10.1007/s40259-017-0248-z
Delivery of Biologics Across the Blood–Brain Barrier with Molecular Trojan Horse Technology
W. Pardridge (2017)
10.3389/fphys.2018.01663
New Approaches to Tay-Sachs Disease Therapy
V. Solovyeva (2018)
10.1134/S0006297914070049
Secondary biochemical and morphological consequences in lysosomal storage diseases
J. Alroy (2014)
10.1007/s13346-012-0072-4
Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders
S. Muro (2012)
10.2217/nnm.12.138
Lysosome-targeted octadecyl-rhodamine B-liposomes enhance lysosomal accumulation of glucocerebrosidase in Gaucher's cells in vitro.
Ritesh V. Thekkedath (2013)
10.4103/2278-344X.107832
Polymeric nanoparticles for drug delivery and targeting: A comprehensive review
N. Jawahar (2012)
10.1038/nature25486
Mitochondria-lysosome contacts regulate mitochondrial fission via Rab7 GTP hydrolysis
Yvette C Wong (2018)
10.14670/HH-26.1093
Neural stem cell-mediated therapy for rare brain diseases: perspectives in the near future for LSDs and MNDs.
L. Filippis (2011)
10.1016/j.expneurol.2017.09.012
Murine Sialidase Neu3 facilitates GM2 degradation and bypass in mouse model of Tay-Sachs disease
V. Seyrantepe (2018)
10.1038/s41419-017-0025-4
Mitochondria-associated ER membranes (MAMs) and lysosomal storage diseases
I. Annunziata (2017)
10.1128/CMR.00008-08
Gene Therapy Using Adeno-Associated Virus Vectors
Shyam Daya (2008)
10.1016/j.bbacli.2017.10.001
Multiple exo-glycosidases in human serum as detected with the substrate DNP-α-GalNAc. I. A new assay for lysosomal α-N-acetylgalactosaminidase
S. P. Albracht (2017)
10.1007/978-1-4939-6934-0_9
Delivery of Cargo to Lysosomes Using GNeosomes.
K. Hamill (2017)
Mucopolysaccharidosis III (Sanfilippo Syndrome)- disease presentation and experimental therapies.
J. Gilkes (2014)
10.1016/j.beem.2014.12.001
Neuronopathic lysosomal storage disorders: Approaches to treat the central nervous system.
M. Scarpa (2015)
10.1016/j.ymgme.2008.01.007
Acidic amino acid tag enhances response to enzyme replacement in mucopolysaccharidosis type VII mice.
A. Montaño (2008)
10.1021/bm2003384
pH-responsive polysaccharide-based polyelectrolyte complexes as nanocarriers for lysosomal delivery of therapeutic proteins.
M. I. Giannotti (2011)
10.1152/physiol.00041.2009
Lysosomal storage disease: revealing lysosomal function and physiology.
E. Parkinson-Lawrence (2010)
10.1093/hmg/ddr610
Impaired parkin-mediated mitochondrial targeting to autophagosomes differentially contributes to tissue pathology in lysosomal storage diseases
Raquel de Pablo-Latorre (2012)
10.1038/gt.2008.149
Mechanisms of distribution of mouse β-galactosidase in the adult GM1-gangliosidosis brain
M. Broekman (2009)
10.1016/S0140-6736(00)02533-2
Recombinant human α-glucosidase from rabbit milk in Pompe patients
H. V. D. Hout (2000)
10.3928/19382359-20180424-01
Enzyme Replacement Therapy: A Review and Its Role in Treating Lysosomal Storage Diseases.
M. Li (2018)
10.2147/IJN.S68861
Liposomes as nanomedical devices
G. Bozzuto (2015)
Arylsulfatase A bound to poly(butyl cyanoacrylate) nanoparticles for enzyme replacement therapy--physicochemical evaluation.
A. Mühlstein (2014)
10.1007/s12098-009-0249-0
Plasma chitotriosidase activity in children with lysosomal storage disorders
J. Sheth (2010)
10.1166/JBN.2014.1718
Enhancing biodistribution of therapeutic enzymes in vivo by modulating surface coating and concentration of ICAM-1-targeted nanocarriers.
Janet Hsu (2014)
10.1016/j.ajhg.2012.05.023
A homozygous mutation in KCTD7 links neuronal ceroid lipofuscinosis to the ubiquitin-proteasome system.
J. Staropoli (2012)
10.1016/j.biomaterials.2013.01.069
In vivo performance of polymer nanocarriers dually-targeted to epitopes of the same or different receptors.
Iason T. Papademetriou (2013)
Enzyme replacement therapy for lysosomal storage diseases.
T. Ohashi (2012)
10.1016/j.cell.2010.02.024
Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids
Y. Sancak (2010)
Mucopolysaccharidosis type VII: A powerful experimental system and therapeutic challenge.
M. Sands (2014)
10.1016/j.ejpb.2017.10.017
Gene editing of MPS I human fibroblasts by co‐delivery of a CRISPR/Cas9 plasmid and a donor oligonucleotide using nanoemulsions as nonviral carriers
R. Schuh (2018)
10.1089/hum.2017.163
Adeno-Associated Virus Gene Therapy in a Sheep Model of Tay-Sachs Disease.
H. Gray-Edwards (2018)
10.2174/0929867323666160210130608
Role of Nanotechnology for Enzyme Replacement Therapy in Lysosomal Diseases. A Focus on Gaucher's Disease.
L. Martín-Banderas (2016)
10.1186/s13023-018-0903-6
A health state utility valuation study to assess the impact of treatment mode of administration in Gaucher disease
M. Hadi (2018)
10.1016/j.ajhg.2012.04.021
Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage.
K. Smith (2012)
10.1007/s11064-012-0718-0
Therapeutic Effects of Stem Cells and Substrate Reduction in Juvenile Sandhoff Mice
J. R. Arthur (2012)
10.1056/NEJM200101183440304
Enzyme-replacement therapy in mucopolysaccharidosis I.
E. Kakkis (2001)
10.1093/hmg/ddv086
Combined gene/cell therapies provide long-term and pervasive rescue of multiple pathological symptoms in a murine model of globoid cell leukodystrophy
Alessandra Ricca (2015)
10.1148/rg.2016150168
Neuroimaging Findings in Patients with Mucopolysaccharidosis: What You Really Need to Know.
R. Reichert (2016)
10.1002/iub.1288
Impairment of homeostasis in lysosomal storage disorders
Laura Segatori (2014)
10.1007/s10545-011-9430-5
Intellectual and neurological functioning in Morquio syndrome (MPS IVa)
J. Davison (2011)
10.1523/JNEUROSCI.2936-05.2005
Functional Correction of CNS Phenotypes in a Lysosomal Storage Disease Model Using Adeno-Associated Virus Type 4 Vectors
Gumei Liu (2005)
10.1166/JNN.2015.9251
Use of Polylactide-Co-Glycolide-Nanoparticles for Lysosomal Delivery of a Therapeutic Enzyme in Glycogenosis Type II Fibroblasts.
B. Tancini (2015)
10.2174/138161208784705504
Lysosomal storage diseases and the blood-brain barrier.
D. Begley (2008)
10.1016/j.bbrc.2018.05.037
Drug delivery using polyhistidine peptide-modified liposomes that target endogenous lysosome.
Taiki Hayashi (2018)
10.1002/ajmg.a.38320
Psychiatric and cognitive characteristics of individuals with Danon disease (LAMP2 gene mutation)
Maya Yardeni (2017)
10.1194/jlr.R046896
Lysosomal exocytosis and lipid storage disorders
M. Samie (2014)
10.3109/1061186X.2010.550921
Targeting of lysosomes by liposomes modified with octadecyl-rhodamine B
Alexander Koshkaryev (2011)
10.1051/JBIO/2002196020127
[Lysosomes and lysosomal storage diseases].
D. Germain (2002)
10.1002/mds.25462
Lysosomal impairment in Parkinson's disease
B. Dehay (2013)
10.1016/0006-291X(65)90743-6
METABOLISM OF GLUCOCEREBROSIDES. II. EVIDENCE OF AN ENZYMATIC DEFICIENCY IN GAUCHER'S DISEASE.
R. Brady (1965)
10.1016/j.neuroscience.2015.05.061
Astrocytes and lysosomal storage diseases
K. V. R. Rao (2016)
10.2147/DDDT.S36131
Multicomponent nanoparticles as nonviral vectors for the treatment of Fabry disease by gene therapy
A. P. Ruiz de Garibay (2012)
10.1016/j.addr.2017.05.004
Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives
M. Solomon (2017)
10.1016/j.ymgme.2016.07.011
Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis.
M. Fietz (2016)
10.1016/j.jconrel.2017.02.016
Potential of surfactant‐coated nanoparticles to improve brain delivery of arylsulfatase A
Tilman Schuster (2017)
10.1016/B978-0-444-59565-2.00041-1
Niemann-Pick diseases.
M. Vanier (2013)
10.1097/MOP.0b013e32834c20d9
Enzyme replacement therapy for lysosomal storage diseases
R. Lachmann (2011)
10.1016/S0962-8924(03)00005-9
At the acidic edge: emerging functions for lysosomal membrane proteins.
E. Eskelinen (2003)
10.1016/j.expneurol.2018.04.001
Attenuation of the Niemann-Pick type C2 disease phenotype by intracisternal administration of an AAVrh.10 vector expressing Npc2
S. Markmann (2018)
10.2147/DDDT.S139601
Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future
D. A. Whiteman (2017)
10.1093/hmg/ddv615
Lysosomal dysfunction and impaired autophagy in a novel mouse model deficient for the lysosomal membrane protein Cln7.
L. Brandenstein (2016)
10.2174/138161212800492822
Polymeric nanocarriers and nanoreactors: a survey of possible therapeutic applications.
O. Onaca-Fischer (2012)
10.1016/J.JPEDS.2005.12.014
Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study.
P. Harmatz (2006)
10.1038/nature08710
Hsp70 stabilizes lysosomes and reverts Niemann–Pick disease-associated lysosomal pathology
T. Kirkegaard (2010)
10.1016/j.braindev.2015.07.006
Chemical chaperone treatment for galactosialidosis: Effect of NOEV on β-galactosidase activities in fibroblasts
M. A. Hossain (2016)
10.1371/journal.pone.0156452
Targeted Polymeric Nanoparticles for Brain Delivery of High Molecular Weight Molecules in Lysosomal Storage Disorders
Marika Salvalaio (2016)
10.1016/j.beem.2014.10.001
Metachromatic leukodystrophy: Disease spectrum and approaches for treatment.
Diane F. van Rappard (2015)
Long-circulating and target-specific nanoparticles: theory to practice.
S. Moghimi (2001)
10.2174/1381612822666161227154447
Nano-medicine Improving the Bioavailability of Small Molecules for the Prevention of Neurodegenerative Diseases.
P. Di Martino (2017)
10.1002/jps.23974
Protein nanoparticles for intracellular delivery of therapeutic enzymes.
L. H. Estrada (2014)
10.5483/BMBRep.2015.48.8.101
Glyco-engineering strategies for the development of therapeutic enzymes with improved efficacy for the treatment of lysosomal storage diseases
Doo-Byoung Oh (2015)
10.3941/jrcr.v9i5.2149
Skeletal and Brain Abnormalities in Fucosidosis, a Rare Lysosomal Storage Disorder.
Camille Malatt (2015)
10.1016/j.arcmed.2014.11.020
Cyclodextrins, blood-brain barrier, and treatment of neurological diseases.
M. Vecsernyés (2014)
10.1016/j.msec.2017.06.004
Polymeric nanoparticles: A study on the preparation variables and characterization methods.
Carina Crucho (2017)
10.1016/j.bbrep.2016.04.012
Combined replacement effects of human modified β-hexosaminidase B and GM2 activator protein on GM2 gangliosidoses fibroblasts
Keisuke Kitakaze (2016)
10.1002/path.3021
The cellular pathology of lysosomal diseases
T. Cox (2012)
10.2174/138161211797247578
Gene therapy for lysosomal storage diseases: progress, challenges and future prospects.
S. Seregin (2011)
10.1002/wnan.73
New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders.
S. Muro (2010)
10.1074/jbc.R110.134452
Common and Uncommon Pathogenic Cascades in Lysosomal Storage Diseases*
Einat B. Vitner (2010)
10.1021/nn505073u
Ceria nanoparticles stabilized by organic surface coatings activate the lysosome-autophagy system and enhance autophagic clearance.
W. Song (2014)
10.1002/humu.21184
Pathogenic mutations cause rapid degradation of lysosomal storage disease‐related membrane protein CLN6
Anna-Katherina Kurze (2010)
10.1016/j.xphs.2017.10.038
Lipidic Nanoparticles Comprising Phosphatidylinositol Mitigate Immunogenicity and Improve Efficacy of Recombinant Human Acid Alpha-Glucosidase in a Murine Model of Pompe Disease.
Jennifer L. Schneider (2018)
10.1016/j.jconrel.2010.10.025
Optimizing endothelial targeting by modulating the antibody density and particle concentration of anti-ICAM coated carriers.
A. J. Calderon (2011)
10.1007/s10545-017-0052-4
Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I
Rachele Penati (2017)
10.1016/j.bbadis.2013.05.026
Pathogenesis and therapies for infantile neuronal ceroid lipofuscinosis (infantile CLN1 disease).
Jacqueline A. Hawkins-Salsbury (2013)
10.1002/jgm.1489
Correction of mucopolysaccharidosis type IIIA somatic and central nervous system pathology by lentiviral‐mediated gene transfer
Chantelle Mcintyre (2010)
10.2147/TACG.S57682
Recent advances in gene therapy for lysosomal storage disorders
D. Rastall (2015)
10.1021/bc200336j
Screening and optimization of ligand conjugates for lysosomal targeting.
I. Meerovich (2011)
10.1007/s11427-016-5090-x
Regulation of lysosomal ion homeostasis by channels and transporters
Jian Xiong (2016)
10.1016/j.ejmg.2014.06.005
The early detection of Salla disease through second-tier tests in newborn screening: how to face incidental findings.
M. Couce (2014)
10.2183/pjab.88.18
Pharmacological chaperone therapy for Fabry disease
S. Ishii (2012)
10.1038/mt.2014.138
A chaperone enhances blood α-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy.
G. Parenti (2014)
10.1038/nrm1423
The cell biology of lysosomal storage disorders
A. Futerman (2004)
10.1371/journal.pone.0026741
Exome-Sequencing Confirms DNAJC5 Mutations as Cause of Adult Neuronal Ceroid-Lipofuscinosis
B. Benitez (2011)
10.1083/jcb.201704068
Activity-dependent trafficking of lysosomes in dendrites and dendritic spines
Marisa S Goo (2017)
10.1111/j.1365-2141.2004.05293.x
Lysosomal storage disorders
A. Vellodi (2005)
10.1155/2016/1087250
Design of Nanoparticle-Based Carriers for Targeted Drug Delivery.
Xiaojiao Yu (2016)
10.1038/srep37583
Identification of Small Molecule Compounds for Pharmacological Chaperone Therapy of Aspartylglucosaminuria
Antje Banning (2016)
10.1111/petr.12981
Non‐sibling hematopoietic stem cell transplantation using myeloablative conditioning regimen in children with Maroteaux‐Lamy syndrome: A brief report
M. Behfar (2017)
10.1074/jbc.M112.438663
Glycosylation-independent Lysosomal Targeting of Acid α-Glucosidase Enhances Muscle Glycogen Clearance in Pompe Mice*
J. Maga (2012)
10.1111/jnc.14577
Fundamentals of CNS energy metabolism and alterations in lysosomal storage diseases
M. McKenna (2019)
10.1166/JBN.2015.1968
Solid Lipid Nanoparticles as Non-Viral Vectors for Gene Transfection in a Cell Model of Fabry Disease.
A. P. Ruiz de Garibay (2015)
10.1111/j.0009-9163.2004.00217.x
Gaucher's disease: a paradigm for interventional genetics
D. Germain (2004)
10.3390/diagnostics8020029
Sialidosis: A Review of Morphology and Molecular Biology of a Rare Pediatric Disorder
Aiza Khan (2018)
10.1002/jnr.23762
New therapeutic approaches for Krabbe disease: The potential of pharmacological chaperones
Samantha J. Spratley (2016)
10.1371/journal.pbio.0060026
Partial Restoration of Mutant Enzyme Homeostasis in Three Distinct Lysosomal Storage Disease Cell Lines by Altering Calcium Homeostasis
Ting-Wei Mu (2008)
Development of nanoparticle-bound arylsulfatase B for enzyme replacement therapy of mucopolysaccharidosis VI.
A. Mühlstein (2013)
10.1136/jmedgenet-2015-103322
Clinical course of sly syndrome (mucopolysaccharidosis type VII)
A. Montaño (2016)
10.4155/fmc.14.40
Pharmacological chaperone therapy for lysosomal storage diseases.
G. Parenti (2014)
10.2350/14-05-1500-CR.1
A Case of Galactosialidosis with Novel Mutations of the Protective Protein/Cathepsin A Gene: Diagnosis Prompted by Trophoblast Vacuolization on Placental Examination
S. Kostadinov (2014)
10.1016/j.nano.2011.08.014
Enhanced delivery of α-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders.
Janet Hsu (2012)
10.1093/CLINCHEM/13.7.565
Enzymatic abnormalities in diseases of sphingolipid metabolism.
R. Brady (1967)
10.1155/2016/6365295
Niosome Encapsulation of Curcumin
Y. Xu (2016)
10.3727/096368910X498944
Embryonic Stem Cell-Derived Glial Precursors as a Vehicle for Sulfamidase Production in the MPS-IIIA Mouse Brain
A. Robinson (2010)
10.3390/ijms17030380
A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery
J. C. Leach (2016)
10.1038/mt.2015.62
Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders.
G. Parenti (2015)
10.1016/J.JCONREL.2007.05.022
Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123.
G. Tosi (2007)
10.1016/j.ymgme.2016.12.008
Types A and B Niemann-Pick disease.
Edward H. Schuchman (2017)
10.3390/ijns3020006
Newborn Screening for Lysosomal Storage Diseases: A Concise Review of the Literature on Screening Methods, Therapeutic Possibilities and Regional Programs
P. Schielen (2017)
10.3390/ijms18020441
A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments
J. Stirnemann (2017)
10.1038/pr.2011.13
Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats
D. Auclair (2012)
10.1080/21675511.2015.1068978
Pompe disease: Shared and unshared features of lysosomal storage disorders
Jeong-A Lim (2015)
10.1016/j.bbamcr.2008.12.001
Lysosomal disorders: from storage to cellular damage.
A. Ballabio (2009)
10.1016/J.JCONREL.2004.10.017
Polymer nanocarriers protecting active enzyme cargo against proteolysis.
T. Dziubla (2005)
10.1074/jbc.M114.621706
Unbiased Cell-based Screening in a Neuronal Cell Model of Batten Disease Highlights an Interaction between Ca2+ Homeostasis, Autophagy, and CLN3 Protein Function*
Uma Chandrachud (2015)
10.1002/jnr.23792
Gene therapy for metachromatic leukodystrophy
Jonathan B. Rosenberg (2016)
10.1016/j.ymgme.2015.06.001
Human recombinant lysosomal enzymes produced in microorganisms.
A. Espejo-Mojica (2015)
10.1002/psc.2430
Peptide‐mediated cell penetration and targeted delivery of gold nanoparticles into lysosomes
Chaitali D Dekiwadia (2012)
10.1016/j.bbrc.2014.12.111
Lysosomal integral membrane protein type-2 (LIMP-2/SCARB2) is a substrate of cathepsin-F, a cysteine protease mutated in type-B-Kufs-disease.
J. Peters (2015)
Alpha-mannosidosis - a review of genetic, clinical findings and options of treatment.
L. Borgwardt (2014)
10.1007/s10545-010-9075-9
Pathophysiology of neuropathic lysosomal storage disorders
C. Bellettato (2010)
10.1007/s12035-014-8832-4
Genetic Convergence of Parkinson’s Disease and Lysosomal Storage Disorders
H. Deng (2014)
10.1038/srep31750
PEG-lipid micelles enable cholesterol efflux in Niemann-Pick Type C1 disease-based lysosomal storage disorder
A. Brown (2016)
10.1080/1061186X.2017.1349771
ICAM-1 targeting, intracellular trafficking, and functional activity of polymer nanocarriers coated with a fibrinogen-derived peptide for lysosomal enzyme replacement
C. Garnacho (2017)
10.1385/MN:32:1:027
Lysosomal membrane proteomics and biogenesis of lysosomes
Richard D. Bagshaw (2007)
10.1016/j.foodchem.2014.05.118
Delivery of phytochemicals of tropical fruit by-products using poly (DL-lactide-co-glycolide) (PLGA) nanoparticles: synthesis, characterization, and antimicrobial activity.
L. Silva (2014)
10.1038/gim.2015.24
Novel first-dose adverse drug reactions during a phase I trial of olipudase alfa (recombinant human acid sphingomyelinase) in adults with Niemann–Pick disease type B (acid sphingomyelinase deficiency)
M. Mcgovern (2016)
10.1089/HUM.2016.088
Stem Cell Therapy for the Central Nervous System in Lysosomal Storage Diseases.
SiddiqiFaez (2016)
10.1001/JAMA.285.21.2743
Enzyme replacement therapy in Fabry disease: a randomized controlled trial.
R. Schiffmann (2001)
10.1007/s00253-016-7689-z
α-Galactosidase delivery using 30Kc19-human serum albumin nanoparticles for effective treatment of Fabry disease
Hong Jai Lee (2016)
rs as pharmacological chaperones for Krabbe disease † ‡
C. Hill (2015)
10.1016/j.ejpb.2016.10.016
Applications of lipid nanoparticles in gene therapy.
A. Del Pozo-Rodríguez (2016)
10.1016/j.ymgme.2011.06.006
Mucolipidosis type IV: an update.
Kazuyo Wakabayashi (2011)
10.1007/978-1-60327-360-2_8
Liposome formulations of hydrophobic drugs.
R. Schwendener (2010)
10.1007/978-3-319-08894-5_2
Glutamate metabolism in the brain focusing on astrocytes.
A. Schousboe (2014)
10.1016/j.ymgme.2015.08.008
From rare to common and back again: 60years of lysosomal dysfunction.
M. Coutinho (2016)
10.1080/15548627.2015.1136769
Nanoparticles restore lysosomal acidification defects: Implications for Parkinson and other lysosomal-related diseases
M. Bourdenx (2016)
10.1002/ddrr.1117
Newborn screening for lysosomal storage disorders and other neuronopathic conditions.
D. Matern (2013)
10.3109/21691401.2015.1008503
Formulation, characterization, and evaluation of ligand-conjugated biodegradable quercetin nanoparticles for active targeting
A. Gupta (2016)
10.1016/j.bbadis.2015.06.003
Bridging NCL research gaps.
F. Stehr (2015)
10.1089/hum.2008.022
Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA.
S. Worgall (2008)
10.1016/J.YMTHE.2005.09.020
Histopathological and behavioral improvement of murine mucopolysaccharidosis type VII by intracerebral transplantation of neural stem cells.
Y. Fukuhara (2006)
10.1126/science.1233158
Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy
A. Biffi (2013)
10.1002/1615-9861(200208)2:8<1026::AID-PROT1026>3.0.CO;2-I
Proteomic analysis of human lysosomes: Application to monocytic and breast cancer cells
A. Journet (2002)
10.2147/IJN.S81156
Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor
X. Li (2016)
10.1124/MI.3.2.90
Blood-brain barrier drug targeting: the future of brain drug development.
W. Pardridge (2003)
10.1002/emmm.201202176
Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease
C. Spampanato (2013)
10.1016/j.ymgmr.2018.08.005
Quantification of 11 enzyme activities of lysosomal storage disorders using liquid chromatography-tandem mass spectrometry
Mari Ohira (2018)
10.1016/j.ejpb.2011.06.005
Understanding the mechanism of protamine in solid lipid nanoparticle-based lipofection: the importance of the entry pathway.
D. Delgado (2011)
10.1111/age.12629
Neuronal ceroid lipofuscinosis in Salukis is caused by a single base pair insertion in CLN8
F. Lingaas (2018)
10.1523/JNEUROSCI.4785-13.2014
Comparison of Five Peptide Vectors for Improved Brain Delivery of the Lysosomal Enzyme Arylsulfatase A
A. Böckenhoff (2014)
10.1002/humu.22443
Topology and Membrane Anchoring of the Lysosomal Storage Disease‐Related Protein CLN5
Heidi Larkin (2013)
10.1124/jpet.111.185579
A Fibrinogen-Derived Peptide Provides Intercellular Adhesion Molecule-1-Specific Targeting and Intraendothelial Transport of Polymer Nanocarriers in Human Cell Cultures and Mice
C. Garnacho (2012)
10.4161/auto.6.8.13378
Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder—murine Pompe disease
N. Raben (2010)
10.1111/cge.12071
Mutation identification of Fabry disease in families with other lysosomal storage disorders
A. Zampetti (2013)
10.1038/nrneurol.2013.163
Lysosomal storage diseases—the horizon expands
R. Boustany (2013)
Hematopoietic stem cell transplant for lysosomal storage diseases.
T. Lund (2013)
10.1016/j.ccm.2016.04.012
Hermansky-Pudlak Syndrome.
S. El-Chemaly (2016)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar